Tacrolimus versus cyclosporine as primary prophylactic therapy after cadaveric renal transplant: two-year survival study.
Wong
K M
KM
Renal Unit, Department of Medicine, Queen Elizabeth Hospital, SAR, Hong Kong, People's Republic of China.
Cheung
C Y
CY
Chan
Y H
YH
Chak
W L
WL
Choi
K S
KS
Chau
K F
KF
Li
C S
CS
D000328:Adult; D001379:Azathioprine / Q000627:therapeutic use; D002102:Cadaver; D002423:Cause of Death; D016572:Cyclosporine / Q000009:adverse effects / Q000627:therapeutic use*; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology; D006085:Graft Survival / Q000187:drug effects / Q000502:physiology*; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016030:Kidney Transplantation / Q000276:immunology* / Q000401:mortality / Q000502:physiology; D008297:Male; D011239:Prednisolone / Q000627:therapeutic use; D015996:Survival Rate; D016559:Tacrolimus / Q000009:adverse effects / Q000627:therapeutic use*; D013997:Time Factors; D014019:Tissue Donors
D007166:Immunosuppressive Agents; D016572:Cyclosporine; D011239:Prednisolone; D001379:Azathioprine; D016559:Tacrolimus